1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Skinner RS, Wheeler CM, Romanowski B,
Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo RM, Vallejos
C, Minkina G, Pereira Da Silva D, McNeil S, et al: Progression of
HPV infection to detectable cervical lesions or clearance in adult
women: Analysis of the control arm of the VIVIANE study. Int J
Cancer. 138:2428–2438. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Madeleine MM, Anttila T, Schwartz SM,
Saikku P, Leinonen M, Carter JJ, Wurscher M, Johnson LG, Galloway
DA and Daling JR: Risk of cervical cancer associated with Chlamydia
trachomatis antibodies by histology, HPV type and HPV cofactors.
Int J Cancer. 120:650–655. 2007. View Article : Google Scholar : PubMed/NCBI
|
5
|
Choi YJ and Park JS: Clinical significance
of human papillomavirus genotyping. J Gynecol Oncol. 7:e212016.
View Article : Google Scholar
|
6
|
Egawa N, Egawa K, Griffin H and Doorbar J:
Human papillomaviruses: epithelial tropisms, and the development of
neoplasia. Viruses. 7:3863–3890. 2015. View
Article : Google Scholar : PubMed/NCBI
|
7
|
Bellanger S, Tan CL, Xue YZ, Teissier S
and Thierry F: Tumor suppressor or oncogene? A critical role of the
human papillomavirus (HPV) E2 protein in cervical cancer
progression. Am J Cancer Res. 1:373–389. 2011.PubMed/NCBI
|
8
|
Doorbar J, Egawa N, Griffin H, Kranjec C
and Murakami I: Human papillomavirus molecular biology and disease
association. Rev Med Virol. 25 (Suppl 1):S2–S23. 2015. View Article : Google Scholar
|
9
|
Wang JT, Ding L, Gao ES and Cheng YY:
Analysis on the expression of human papillomavirus type 16 E2 and
E6 oncogenes and disruption of E2 in cervical cancer. Zhonghua Liu
Xing Bing Xue Za Zhi. 28:968–971. 2007.(In Chinese). PubMed/NCBI
|
10
|
Missaoui N, Trabelsi A, Landolsi H,
Jaidaine L, Mokni M, Korbi S and Hmissa S: Cervical adenocarcinoma
and squamous cell carcinoma incidence trends among Tunisian women.
Asian Pac J Cancer Prev. 11:777–780. 2010.PubMed/NCBI
|
11
|
Wang SS, Sherman ME, Hildesheim A, Lacey
JV Jr and Devesa S: Cervical adenocarcinoma and squamous cell
carcinoma incidence trends among white women and black women in the
United States for 1976–2000. Cancer. 100:1035–1044. 2004.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Auborn KJ, Woodworth C, DiPaolo JA and
Bradlow HL: The interaction between HPV infection and estrogen
metabolism in cervical carcinogenesis. Int J Cancer. 49:867–869.
1991. View Article : Google Scholar : PubMed/NCBI
|
13
|
Newfield L, Bradlow HL, Sepkovic DW and
Auborn K: Estrogen metabolism and the malignant potential of human
papillomavirus immortalized keratinocytes. Proc Soc Exp Biol Med.
217:322–326. 1998. View Article : Google Scholar : PubMed/NCBI
|
14
|
Moodley M, Moodley J, Chetty R and
Herrington CS: The role of steroid contraceptive hormones in the
pathogenesis of invasive cervical cancer: A review. Int J Gynecol
Cancer. 13:103–110. 2003. View Article : Google Scholar : PubMed/NCBI
|
15
|
Salazar EL, Sojo-Aranda I, Lopez R and
Salcedo M: The evidence for an etiological relationship between
oral contraceptive use and dysplastic change in cervical tissue.
Gynecol Endocrinol. 15:23–28. 2001. View Article : Google Scholar : PubMed/NCBI
|
16
|
Muñoz N, Franceschi S, Bosetti C, Moreno
V, Herrero R, Smith JS, Shah KV, Meijer CJ and Bosch FX;:
International Agency for Research on Cancer (IARC) Multicentric
Cervical Cancer Study Group: Role of parity and human
papillomavirus in cervical cancer: The IARC multicentric
case-control study. Lancet. 359:1093–1101. 2002. View Article : Google Scholar : PubMed/NCBI
|
17
|
Plapinger L and Bern HA: Adenosis-like
lesions and other cervicovaginal abnormalities in mice treated
perinatally with estrogen. J Natl Cancer Inst. 63:507–518.
1979.PubMed/NCBI
|
18
|
McLachlan JA, Newbold RR and Bullock BC:
Long-term effects on the female mouse genital tract associated with
prenatal exposure to diethylstilbestrol. Cancer Res. 40:3988–3999.
1980.PubMed/NCBI
|
19
|
Liu Y, Tian LB, Yang HY and Zhang HP:
Effects of estradiol and progesterone on the growth of HeLa
cervical cancer cells. Eur Rev Med Pharmacol Sci. 21:3959–3965.
2017.PubMed/NCBI
|
20
|
Brake T and Lambert PF: Estrogen
contributes to the onset, persistence, and malignant progression of
cervical cancer in a human papillomavirus-transgenic mouse model.
Proc Natl Acad Sci USA. 102:2490–2495. 2005. View Article : Google Scholar : PubMed/NCBI
|
21
|
den Boon JA, Pyeon D, Wang SS, Horswill M,
Schiffman M, Sherman M, Zuna RE, Wang Z, Hewitt SM, Pearson R, et
al: Molecular transitions from papillomavirus infection to cervical
precancer and cancer: Role of stromal estrogen receptor signaling.
Proc Natl Acad Sci USA. 112:E3255–E3264. 2015. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhang SK, Kang LN, Chang IJ, Zhao FH, Hu
SY, Chen W, Shi JF, Zhang X, Pan QJ, Li SM, et al: The natural
history of cervical cancer in Chinese women: results from an
11-year follow-up study in china using a multistate model. Cancer
Epidemiol Biomarkers Prev. 23:1298–1305. 2014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Sambrook J and Russell DW: Purification of
nucleic acids by extraction with phenol:chloroform. CSH Protoc.
2006(pii): pdb.prot4455. 2006.
|
24
|
Yoshikawa H, Kawana T, Kitagawa K, Mizuno
M, Yoshikura H and Iwamoto A: Detection and typing of multiple
genital human papillomaviruses by DNA amplification with consensus
primers. Jpn J Cancer Res. 82:524–531. 1991. View Article : Google Scholar : PubMed/NCBI
|
25
|
Badaracco G, Venuti A, Sedati A and
Marcante ML: HPV16 and HPV18 in genital tumors: Significantly
different levels of viral integration and correlation to tumor
invasiveness. J Med Virol. 67:574–582. 2002. View Article : Google Scholar : PubMed/NCBI
|
26
|
Knol MJ and VanderWeele TJ:
Recommendations for presenting analyses of effect modification and
interaction. Int J Epidemiol. 41:514–520. 2012. View Article : Google Scholar : PubMed/NCBI
|
27
|
Rothman KJ, Greenland S and Lash TL:
Chapter 5 Concepts of Interaction. In: Modern epidemiology.
Lippincott Williams & Wilkins. 2008.
|
28
|
Goodman MT, Shvetsov YB, McDuffie K,
Wilkens LR, Zhu X, Ning L, Killeen J, Kamemoto L and Hernandez BY:
Acquisition of anal human papillomavirus (HPV) infection in women:
The Hawaii HPV Cohort study. J Infect Dis. 197:957–966. 2008.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Shvetsov YB, Hernandez BY, McDuffie K,
Wilkens LR, Zhu X, Ning L, Killeen J, Kamemoto L and Goodman MT:
Duration and clearance of anal human papillomavirus (HPV) infection
among women: The Hawaii HPV cohort study. Clin Infect Dis.
48:536–546. 2009. View
Article : Google Scholar : PubMed/NCBI
|
30
|
Chen HC, Schiffman M, Lin CY, Pan MH, You
SL, Chuang LC, Hsieh CY, Liaw KL, Hsing AW, Chen CJ, et al:
Persistence of type-specific human papillomavirus infection and
increased long-term risk of cervical cancer. J Natl Cancer Inst.
103:1387–1396. 2011. View Article : Google Scholar : PubMed/NCBI
|
31
|
Byun JM, Jeong DH, Kim YN, Jung EJ, Lee
KB, Sung MS and Kim KT: Persistent HPV-16 infection leads to
recurrence of high-grade cervical intraepithelial neoplasia.
Medicine (Baltimore). 97:e136062018. View Article : Google Scholar : PubMed/NCBI
|
32
|
Dai M, Bao YP, Li N, Clifford GM,
Vaccarella S, Snijders PJ, Huang RD, Sun LX, Meijer CJ, Qiao YL and
Franceschi S: Human papillomavirus infection in Shanxi Province,
People's Republic of China: A population-based study. Br J Cancer.
95:96–101. 2006. View Article : Google Scholar : PubMed/NCBI
|
33
|
Guo J, Zhao F, Liu R and Mu Y: Prevalence
and type distribution of human papillomavirus infection in women
from Datong, China. Scand J Infect Dis. 42:72–75. 2010. View Article : Google Scholar : PubMed/NCBI
|
34
|
Briolat J, Dalstein V, Saunier M, Joseph
K, Caudroy S, Prétet JL, Birembaut P and Clavel C: HPV prevalence,
viral load and physical state of HPV-16 in cervical smears of
patients with different grades of CIN. Int J Cancer. 121:2198–2204.
2010. View Article : Google Scholar
|
35
|
Luhn P, Walker J, Schiffman M, Zuna RE,
Dunn ST, Gold MA, Smith K, Mathews C, Allen RA, Zhang R, et al: The
role of co-factors in the progression from human papillomavirus
infection to cervical cancer. Gynecol Oncol. 128:265–270. 2013.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Moreno V, Bosch FX, Munoz N, Meijer CJ,
Shah KV, Walboomers JM, Herrero R and Franceschi S;: International
Agency for Research on Cancer. Multicentric Cervical Cancer Study
Group: Effect of oral contraceptives on risk of cervical cancer in
women with human papillomavirus infection: The IARC multicentric
case-control study. Lancet. 359:1085–1092. 2002. View Article : Google Scholar : PubMed/NCBI
|
37
|
Santos Filho MV, Gurgel AP, Lobo CD,
Freitas AC, Silva-Neto JC and Silva LA: Prevalence of human
papillomavirus (HPV), distribution of HPV types, and risk factors
for infection in HPV-positive women. Genet Mol Res. 15:2016.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Siristatidis C, Sergentanis TN, Kanavidis
P, Trivella M, Sotiraki M, Mavromatis I, Psaltopoulou T, Skalkidou
A and Petridou ET: Controlled ovarian hyperstimulation for IVF:
Impact on ovarian, endometrial and cervical cancer-a systematic
review and meta-analysis. Hum Reprod Update. 19:105–123. 2013.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Lundqvist M, Westin C, Lundkvist O,
Simberg N, Strand A, Andersson S and Wilander E: Cytologic
screening and human papilloma virus test in women undergoing
artificial fertilization. Acta Obstet Gynecol Scand Oct.
81:949–953. 2002. View Article : Google Scholar
|
40
|
International Collaboration of
Epidemiological Studies of Cervical Cancer, ; Appleby P, Beral V,
Berrington de González A, Colin D, Franceschi S, Goodhill A, Green
J, Peto J, Plummer M and Sweetland S: Cervical cancer and hormonal
contraceptives: collaborative reanalysis of individual data for
16,573 women with cervical cancer and 35,509 women without cervical
cancer from 24 epidemiological studies. Lancet. 370:1609–1621.
2007. View Article : Google Scholar : PubMed/NCBI
|
41
|
Rinaldi S, Plummer M, Biessy C,
Castellsagué X, Overvad K, Krüger Kjær S, Tjønneland A,
Clavel-Chapelon F, Chabbert-Buffet N, Mesrine S, et al: Endogenous
sex steroids and risk of cervical carcinoma: results from the EPIC
study. Cancer Epidemiol Biomarkers Prev. 20:2532–2540. 2011.
View Article : Google Scholar : PubMed/NCBI
|
42
|
Shields TS, Falk RT, Herrero R, Schiffman
M, Weiss NS, Bratti C, Rodriguez AC, Sherman ME, Burk RD and
Hildesheim A: A case-control study of endogenous hormones and
cervical cancer. Br J Cancer. 90:146–152. 2004. View Article : Google Scholar : PubMed/NCBI
|
43
|
Spurgeon ME, den Boon JA, Horswill M,
Barthakur S, Forouzan O, Rader JS, Beebe DJ, Roopra A, Ahlquist P
and Lambert PF: Human papillomavirus oncogenes reprogram the
cervical cancer microenvironment independently of and
synergistically with estrogen. Proc Natl Acad Sci USA.
114:E9076–E9085. 2017. View Article : Google Scholar : PubMed/NCBI
|
44
|
Kuhl H: Pharmacology of estrogens and
progestogens: Influence of different routes of administration.
Climacteric. 8 (Suppl 1):S3–S63. 2005. View Article : Google Scholar
|
45
|
Adurthi S, Kumar MM, Vinodkumar HS,
Mukherjee G, Krishnamurthy H, Acharya KK, Bafna UD, Uma DK,
Abhishekh B, Krishna S, et al: Oestrogen receptor-α binds the FOXP3
promoter and modulates regulatory T-cell function in human cervical
cancer. Sci Rep. 7:172892017. View Article : Google Scholar : PubMed/NCBI
|
46
|
Blachon S and Demeret C: The regulatory E2
proteins of human genital papillomaviruses are pro-apoptotic.
Biochimie. 85:813–819. 2003. View Article : Google Scholar : PubMed/NCBI
|
47
|
Riley RR, Duensing S, Brake T, Münger K,
Lambert PF and Arbeit JM: Dissection of human papillomavirus E6 and
E7 function in transgenic mouse models of cervical carcinogenesis.
Cancer Res. 63:4862–4871. 2003.PubMed/NCBI
|
48
|
Shai A, Brake T, Somoza C and Lambert PF:
The human papillomavirus E6 oncogene dysregulates the cell cycle
and contributes to cervical carcinogenesis through two independent
activities. Cancer Res. 67:1626–1635. 2007. View Article : Google Scholar : PubMed/NCBI
|
49
|
Arbeit JM, Howley PM and Hanahan D:
Chronic estrogen-induced cervical and vaginal squamous
carcinogenesis in human papillomavirus type 16 transgenic mice.
Proc Natl Acad Sci USA. 93:2930–2935. 1996. View Article : Google Scholar : PubMed/NCBI
|